-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KofUCXjVQEl10D3cgB2F8VkxeUq3Rh+Brc+/W/tIkZ0c70XcoM5rf1dBBaHCxyF1 wVg8o4QlNW3YAU2qw1c0/g== 0001209191-03-001327.txt : 20030304 0001209191-03-001327.hdr.sgml : 20030304 20030304094621 ACCESSION NUMBER: 0001209191-03-001327 CONFORMED SUBMISSION TYPE: 5 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030304 FILED AS OF DATE: 20030304 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GUILFORD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000918066 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521841960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 5 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23736 FILM NUMBER: 03590417 BUSINESS ADDRESS: STREET 1: 6611 TRIBUTARY ST CITY: BALTIMORE STATE: MD ZIP: 21224 BUSINESS PHONE: 4106316300 REPORTING-OWNER: COMPANY DATA: COMPANY CONFORMED NAME: SLUSHER BARBARA S CENTRAL INDEX KEY: 0001206357 RELATIONSHIP: OFFICER FILING VALUES: FORM TYPE: 5 BUSINESS ADDRESS: STREET 1: 6611 TRIBUTARY STREET STREET 2: C/O GUILFORD PHARMACEUTICALS INC CITY: BALTIMORE STATE: MD ZIP: 21224 BUSINESS PHONE: 4106316300 MAIL ADDRESS: STREET 1: C/O GUILFORD PHARMACEUTICALS INC STREET 2: 6611 TIBUTARY ST. CITY: BALTIMORE STATE: MD ZIP: 21224 5 1 i1909.htm FORM 5 SUBMISSION

OMB APPROVAL
OMB Number: 3235-0362
Expires: January 31, 2005
Estimated average burden
hours per response...1.0


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 5

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(h) of the Investment Company Act of 1940

o Check box if no longer
subject to Section 16.
Form 4 or Form 5
obligations may continue.
See Instruction 1(b).
o Form 3 Holdings Reported
o Form 4 Transactions Reported
1. Name and Address of Reporting
Person*		 2. Issuer Name and Ticker or Trading
Symbol		 3. I.R.S. Identification Number of Reporting
Person, if an entity (Voluntary)
  Slusher, Barbara, S.
(Last) (First) (Middle)		   Guilford Pharmaceuticals Inc. (glfd)
  
   
                 
  6611 Tributary Street
 4. Statement for Month/Year 5. If Amendment, Date of Original (Month/Year)
    12/31/2002
  
  (Street) 6. Relationship of Reporting Person(s)
to Issuer (Check All Applicable)		 7. Individual or Joint/Group Reporting
(Check Applicable Line)
  Baltimore, MD 21224
(City)        (State)        (Zip)		   o  Director o  10% Owner   x Form filed by One Reporting Person
    x  Officer (give title below)   o Form filed by More than One Reporting Person
    o  Other (specify below)  
      SVP, Research
     
*   If the form is filed by more than one reporting person, see instruction 4(b)(v).

                                     
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of
Security
(Instr. 3)		 2. Transaction
Date
(Month/Day/Year)		 2A. Deemed Execution
Date, if any
(Month/Day/Year)		 3. Transaction
Code
(Instr. 8)		 4. Securities Acquired (A)
or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities
Beneficially Owned
at the End of Issuer's
Fiscal Year
(Instr. 3 and 4)		 6. Ownership
Form:
Direct (D) or
Indirect (I)
(Instr. 4)		 7. Nature of
Indirect
Beneficial
Ownership
(Instr. 4)
                    Amount (A)
or
(D)		 Price            
  Common Stock   12/31/2002     J (1)   201   A 3.98     443     I   By 401(k)

Page 3

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
  (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative
Security
(Instr. 3)		 2. Conversion or Exercise
Price of Derivative
Security		 3. Transaction Date
(Month/Day/Year)		 3A. Deemed Execution
Date, if any
(Month/Day/Year)		 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities
Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
                            (A) (D)
  Stock Options (Right to buy)     $3.50          
  Stock Options (Right to buy)     $8.81          
  Stock Options (Right to buy)     $8.89          
  Stock Options (Right to buy)     $12.875          
  Stock Options (Right to buy)     $14.9167          
  Stock Options (Right to buy)     $17.625          
  Stock Options (Right to buy)     $19.31          
  Stock Options (Right to buy)     $19.75          
  Stock Options (Right to buy)     $29.8125          

Page 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned - Continued
(e.g., puts, calls, warrants, options, convertible securities)
6. Date Exercisable and
Expiration Date
(Month/Day/Year)		 7. Title and Amount of
Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative
Security
(Instr. 5)		 9. Number of Derivative
Securities Beneficially
Owned at End of
Year
(Instr. 4)		 10. Ownership of
Derivative Security:
Direct (D)
or Indirect (I)
(Instr. 4)		 11. Nature of
Indirect
Beneficial
Ownership
(Instr. 4)
  Date
Exercisable		 Expiration
Date		   Title Amount or
Number of
Shares		                        
  01/09/2005             11,250     D  
  02/20/2012             20,000     D  
  09/24/2011             500     D  
  02/23/2009             5,200     D  
  02/23/2006             6,833     D  
  12/02/2006             8,000     D  
  02/19/2011             16,250     D  
  02/17/2008             10,000     D  
  02/15/2010             7,900     D  

Explanation of Responses:

(1) Shares issued to 401(k) plan account of reporting person as part of company match program; amounts vest in participation accounts 25% per year based on years of service with company.

Asher M. Rubin, Attorney-in-Fact   3/4/2003
**Signature of Reporting Person		  
Date

**   Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 
Note:   File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure.

Page 5

 -----END PRIVACY-ENHANCED MESSAGE-----